Roy J W, Mayrovitz H N
Hypertension. 1984 Nov-Dec;6(6 Pt 1):877-86. doi: 10.1161/01.hyp.6.6.877.
Microvascular resistance (MVR), determined as the ratio of the second-order arteriolar blood pressure (servo-null method) to blood flow (dual-slit), was assessed in the cremaster muscle preparation of 7- to 8-week-old normotensive Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR). The MVR was used as an index of resistance during 1) control conditions; 2) superfusion of graded concentrations of the catecholamine norepinephrine (NE; WKY n = 8, SHR n = 8); 3) superfusion with NE and in the presence of a fixed concentration of the vasodilator sodium nitroprusside (NP; 10(-5) M); and 4) superfusion with the noncatecholamine phenylephrine (PE; WKY n = 8, SHR n = 9). The vasoconstrictor challenges were carried out to determine if there was any differential vascular sensitivity between the hypertensive and nonhypertensive rats to the exposure of an endogenous-like constrictor possessing a catechol nucleus as opposed to a strictly synthetic analog. The presence of NP was employed to assess the degree of vasoconstriction normally present under control conditions. The combination of NE and NP was used to test for a differential vasoconstrictor sensitivity, beginning from maximally dilated conditions. The MVR, assessed at the second-order arteriolar level, represents approximately 35% of the total resistance of the skeletal muscle and is intimately involved in maintaining proper end-organ perfusion pressure. The microvascular resistance of the SHR group was almost four times greater than that of the WKY group under control conditions. Maximum vasodilation with topical NP reduced the MVR in both groups, but the SHR microvascular resistance remained two times greater than that found in the WKY. The SHR had greater MVR responses following challenge with both NE and PE and also in the presence of NP during NE challenge. The conclusions are: 1) the microvascular resistance of the SHR is elevated under control conditions due to structural modifications of the vasculature and exacerbated following constrictor challenge as a result of heightened vasoconstrictor sensitivity; and 2) the elevated MVR in the SHR is not due to a simple arterial vasoconstriction that can be totally eliminated with vasodilation.
微血管阻力(MVR)通过二阶小动脉血压(伺服零位法)与血流量(双缝法)的比值来确定,在7至8周龄的正常血压Wistar-Kyoto(WKY)大鼠和自发性高血压大鼠(SHR)的提睾肌制备物中进行评估。MVR被用作以下情况下的阻力指标:1)对照条件;2)灌注分级浓度的儿茶酚胺去甲肾上腺素(NE;WKY n = 8,SHR n = 8);3)在存在固定浓度血管扩张剂硝普钠(NP;10(-5) M)的情况下用NE灌注;4)用非儿茶酚胺苯肾上腺素(PE;WKY n = 8,SHR n = 9)灌注。进行血管收缩挑战以确定高血压大鼠和非高血压大鼠对具有儿茶酚核的内源性样收缩剂与严格合成类似物暴露的血管敏感性是否存在差异。使用NP来评估对照条件下通常存在的血管收缩程度。NE和NP的组合用于从最大扩张状态开始测试血管收缩敏感性的差异。在二阶小动脉水平评估的MVR约占骨骼肌总阻力的35%,并密切参与维持适当的终末器官灌注压力。在对照条件下,SHR组的微血管阻力几乎是WKY组的四倍。局部使用NP的最大血管扩张降低了两组的MVR,但SHR的微血管阻力仍比WKY组高两倍。在NE和PE挑战后以及在NE挑战期间存在NP的情况下,SHR的MVR反应更大。结论是:1)由于血管结构改变,SHR在对照条件下微血管阻力升高,并且由于血管收缩敏感性增强,在收缩剂挑战后加剧;2)SHR中升高的MVR不是由于简单的动脉血管收缩,这种收缩可以通过血管扩张完全消除。